Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
China SXT Pharmaceuticals, Inc., a pharmaceutical company specializing in the research, development, manufacturing, and sales of Traditional Chinese Medicine Pieces (TCMPs), has entered into a securities purchase agreement with an investor for the sale of 200,000 ordinary shares, raising gross proceeds of approximately $100,000. This transaction was finalized on Monday, with the company disclosing the details in a report filed with the U.S. Securities and Exchange Commission today.
The offering, which closed on May 12, 2025, was conducted under a prospectus supplement filed with the SEC as part of a shelf registration statement on Form F-3, which became effective on November 4, 2024. The base prospectus for this offering was dated October 22, 2024. As a result of this offering, the total number of issued and outstanding ordinary shares of the company is now 16,027,758.
The company has stated that the proceeds from the offering are expected to be $100,000 before the deduction of offering expenses. However, the specific use of these funds has not been disclosed. The securities were issued pursuant to the registration statement previously filed and declared effective, with the sale conducted in compliance with the applicable securities laws.
China SXT Pharmaceuticals has made it clear that the report on Form 6-K shall not be considered as an offer to sell or a solicitation of an offer to buy any securities.
The details provided in the SEC filing are strictly factual and are based on the company’s official statement. The information presented is intended for investors and the broader market to understand the recent financial activities of China SXT Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.